Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Elaine Lam

Concepts (249)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Renal Cell
30
2024
168
6.580
 Why?
Kidney Neoplasms
33
2024
324
6.240
 Why?
Prostatic Neoplasms
13
2023
913
3.200
 Why?
Neoplasms, Germ Cell and Embryonal
3
2023
62
1.600
 Why?
Antineoplastic Agents
13
2023
1875
1.360
 Why?
Prostate-Specific Antigen
4
2023
150
1.260
 Why?
Neoplasms
10
2023
2086
1.140
 Why?
Antineoplastic Combined Chemotherapy Protocols
14
2023
1356
1.120
 Why?
Protein Kinase Inhibitors
11
2021
784
1.020
 Why?
Antibodies, Monoclonal, Humanized
9
2023
660
1.010
 Why?
Testicular Neoplasms
3
2023
96
1.000
 Why?
Seminoma
2
2021
17
0.860
 Why?
Carcinoma, Medullary
2
2013
14
0.780
 Why?
Retroperitoneal Neoplasms
1
2021
22
0.740
 Why?
Antineoplastic Agents, Immunological
1
2023
152
0.740
 Why?
Male
52
2024
55396
0.720
 Why?
Aged
30
2024
18969
0.710
 Why?
Teratoma
1
2021
92
0.710
 Why?
Pneumocystis carinii
1
2020
7
0.690
 Why?
Spinal Cord Compression
1
2020
17
0.690
 Why?
Pneumonia, Pneumocystis
1
2020
24
0.690
 Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2020
38
0.680
 Why?
Euterpe
1
2018
5
0.630
 Why?
Pyrazoles
3
2022
361
0.610
 Why?
Humans
71
2024
114045
0.600
 Why?
Prednisone
3
2020
229
0.590
 Why?
TWEAK Receptor
1
2017
5
0.590
 Why?
Sulfonamides
3
2015
444
0.580
 Why?
Abiraterone Acetate
1
2017
14
0.560
 Why?
Neoplasm Recurrence, Local
3
2023
850
0.560
 Why?
Middle Aged
31
2024
26605
0.550
 Why?
Plant Extracts
1
2018
154
0.550
 Why?
Brain Neoplasms
2
2021
966
0.540
 Why?
Pyridines
4
2021
419
0.540
 Why?
Adrenal Cortex Hormones
1
2020
493
0.540
 Why?
Neoplasm Metastasis
9
2020
521
0.530
 Why?
Antineoplastic Agents, Hormonal
2
2015
138
0.520
 Why?
Carcinoma, Papillary
1
2015
74
0.490
 Why?
Paclitaxel
3
2022
190
0.470
 Why?
Prostatic Neoplasms, Castration-Resistant
3
2022
40
0.460
 Why?
Antibodies, Monoclonal
2
2017
1257
0.450
 Why?
Interleukin-2
2
2014
413
0.450
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.440
 Why?
Biomarkers, Tumor
5
2016
1032
0.430
 Why?
Retrospective Studies
17
2024
12521
0.430
 Why?
Carcinoma, Transitional Cell
2
2023
53
0.420
 Why?
Nephrectomy
4
2024
149
0.400
 Why?
Epothilones
1
2011
1
0.390
 Why?
Androgen Antagonists
3
2020
69
0.380
 Why?
Angiomyolipoma
1
2011
17
0.380
 Why?
Deoxycytidine
2
2010
138
0.370
 Why?
Multicenter Studies as Topic
1
2012
249
0.370
 Why?
Treatment Outcome
14
2022
9049
0.370
 Why?
Aged, 80 and over
12
2024
6306
0.360
 Why?
Anilides
4
2021
67
0.360
 Why?
Urinary Bladder Neoplasms
2
2023
196
0.360
 Why?
Benzenesulfonates
1
2010
19
0.350
 Why?
Suramin
1
2010
6
0.350
 Why?
Radiosurgery
3
2019
299
0.330
 Why?
Immunotherapy
5
2024
473
0.330
 Why?
Patient Reported Outcome Measures
3
2020
251
0.330
 Why?
Maximum Tolerated Dose
6
2022
183
0.320
 Why?
Fluorouracil
1
2008
152
0.300
 Why?
Bone Neoplasms
2
2023
191
0.290
 Why?
Adult
21
2024
30375
0.290
 Why?
Neoplasm Staging
7
2017
1162
0.280
 Why?
Chemotherapy, Adjuvant
3
2013
332
0.280
 Why?
Quinazolines
1
2008
240
0.280
 Why?
Thyroid Neoplasms
1
2010
271
0.270
 Why?
Lung Neoplasms
3
2020
2159
0.270
 Why?
Carcinoma, Non-Small-Cell Lung
2
2015
959
0.260
 Why?
Prognosis
5
2023
3315
0.260
 Why?
Drug Administration Schedule
3
2021
714
0.260
 Why?
Female
27
2024
59324
0.260
 Why?
Sulfones
2
2017
97
0.250
 Why?
Phenylurea Compounds
4
2016
81
0.240
 Why?
Ipilimumab
2
2021
27
0.230
 Why?
Benzoxazoles
2
2022
16
0.220
 Why?
Taxoids
2
2017
93
0.220
 Why?
Platinum
1
2023
38
0.210
 Why?
Disease Progression
2
2021
2371
0.210
 Why?
Bevacizumab
2
2020
114
0.210
 Why?
Mastectomy
1
2023
99
0.210
 Why?
Pyrimidines
3
2022
374
0.200
 Why?
Remission, Spontaneous
1
2021
37
0.190
 Why?
Biliary Tract Neoplasms
1
2021
20
0.180
 Why?
Celecoxib
2
2012
38
0.180
 Why?
Neoplasm, Residual
1
2021
104
0.180
 Why?
Phosphatidylinositol 3-Kinases
1
2022
328
0.180
 Why?
Carboplatin
1
2021
135
0.180
 Why?
Proto-Oncogene Proteins c-akt
1
2022
397
0.180
 Why?
Syndrome
1
2021
330
0.180
 Why?
Combined Modality Therapy
4
2019
1117
0.180
 Why?
Thrombosis
1
2023
295
0.170
 Why?
Urologic Neoplasms
1
2020
24
0.170
 Why?
TOR Serine-Threonine Kinases
1
2022
359
0.170
 Why?
Azepines
1
2020
69
0.170
 Why?
Antiemetics
1
2020
32
0.170
 Why?
Cancer Care Facilities
1
2020
29
0.170
 Why?
Liver Neoplasms
1
2023
504
0.170
 Why?
Homologous Recombination
1
2019
20
0.160
 Why?
Fatal Outcome
1
2020
281
0.160
 Why?
Morpholines
1
2020
102
0.160
 Why?
MAP Kinase Kinase Kinases
1
2019
68
0.160
 Why?
Disease-Free Survival
4
2016
618
0.160
 Why?
Fruit and Vegetable Juices
1
2018
11
0.160
 Why?
Kaplan-Meier Estimate
4
2016
813
0.160
 Why?
Drug Hypersensitivity
1
2020
83
0.150
 Why?
Cost-Benefit Analysis
1
2021
544
0.150
 Why?
Neoplastic Cells, Circulating
2
2016
57
0.150
 Why?
Indans
1
2017
9
0.150
 Why?
Interferon beta-1b
1
2017
2
0.150
 Why?
Niacinamide
3
2016
63
0.140
 Why?
Cell Line, Tumor
3
2020
2700
0.140
 Why?
Neoadjuvant Therapy
2
2023
305
0.140
 Why?
Nanoparticles
1
2021
312
0.140
 Why?
Administration, Oral
3
2022
725
0.140
 Why?
Proton Therapy
1
2017
10
0.140
 Why?
DNA Damage
1
2019
351
0.140
 Why?
Erythrocytes, Abnormal
1
2016
11
0.140
 Why?
Autoimmune Diseases
1
2020
381
0.140
 Why?
Dose-Response Relationship, Drug
3
2022
1836
0.130
 Why?
Multiple Sclerosis, Relapsing-Remitting
1
2017
69
0.130
 Why?
Hematologic Diseases
1
2016
55
0.130
 Why?
Oncolytic Virotherapy
1
2015
8
0.130
 Why?
Indazoles
2
2015
57
0.130
 Why?
Basic Helix-Loop-Helix Transcription Factors
1
2017
225
0.130
 Why?
Mammalian orthoreovirus 3
1
2015
34
0.130
 Why?
Fatigue
2
2022
294
0.130
 Why?
Magnetic Resonance Imaging
2
2021
3039
0.130
 Why?
Pyrroles
1
2016
181
0.130
 Why?
Angiopoietin-1
1
2015
10
0.120
 Why?
Angiopoietin-2
1
2015
11
0.120
 Why?
Imidazoles
2
2015
203
0.120
 Why?
Kidney Glomerulus
1
2015
100
0.120
 Why?
Receptor, IGF Type 1
1
2015
58
0.120
 Why?
Practice Guidelines as Topic
2
2020
1381
0.120
 Why?
Proto-Oncogene Proteins p21(ras)
1
2015
228
0.120
 Why?
Soft Tissue Neoplasms
1
2015
89
0.120
 Why?
Radiation Tolerance
1
2015
92
0.120
 Why?
Indoles
1
2016
300
0.120
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
103
0.110
 Why?
Patient Satisfaction
1
2017
571
0.110
 Why?
Glycine
1
2014
152
0.110
 Why?
Prostatectomy
1
2013
97
0.110
 Why?
Multiple Sclerosis
1
2017
372
0.100
 Why?
Glomerular Filtration Rate
1
2015
605
0.100
 Why?
Recombinant Fusion Proteins
1
2015
613
0.100
 Why?
Quinolines
1
2013
129
0.100
 Why?
Breast Neoplasms
1
2023
1846
0.100
 Why?
Tubulin Modulators
1
2011
9
0.100
 Why?
Metabolic Clearance Rate
1
2011
102
0.090
 Why?
Clinical Trials as Topic
1
2015
926
0.090
 Why?
Arthralgia
1
2011
46
0.090
 Why?
Cohort Studies
4
2021
4883
0.090
 Why?
Anti-Bacterial Agents
1
2020
1471
0.090
 Why?
Area Under Curve
1
2011
273
0.090
 Why?
Survival Rate
3
2020
1638
0.090
 Why?
Mechanistic Target of Rapamycin Complex 1
2
2022
97
0.090
 Why?
Peripheral Nervous System Diseases
1
2011
120
0.090
 Why?
Diarrhea
1
2011
170
0.090
 Why?
Molecular Structure
1
2011
434
0.090
 Why?
Proto-Oncogene Proteins c-ret
1
2010
27
0.090
 Why?
Biopsy
1
2013
1024
0.080
 Why?
Nomograms
1
2010
41
0.080
 Why?
Quality of Life
1
2020
2343
0.080
 Why?
Radiotherapy, Adjuvant
1
2010
182
0.080
 Why?
Drug Synergism
1
2010
315
0.080
 Why?
Immunohistochemistry
1
2013
1624
0.080
 Why?
Infusions, Intravenous
1
2010
370
0.080
 Why?
Capecitabine
1
2008
45
0.080
 Why?
Positron-Emission Tomography
1
2010
260
0.080
 Why?
Melanoma
1
2014
620
0.070
 Why?
Tomography, X-Ray Computed
2
2022
2272
0.070
 Why?
Follow-Up Studies
3
2020
4392
0.070
 Why?
Risk
1
2008
810
0.060
 Why?
Risk Factors
2
2020
8614
0.060
 Why?
Prospective Studies
3
2021
6195
0.060
 Why?
Cytoreduction Surgical Procedures
1
2024
39
0.060
 Why?
Young Adult
3
2020
10444
0.050
 Why?
Cardiovascular Diseases
1
2014
1726
0.050
 Why?
Mastectomy, Segmental
1
2023
76
0.050
 Why?
Disease Management
2
2017
556
0.050
 Why?
Cisplatin
1
2023
262
0.050
 Why?
Nephritis, Interstitial
1
2020
7
0.040
 Why?
International Agencies
1
2020
29
0.040
 Why?
Lymphocytes
1
2022
327
0.040
 Why?
Aurora Kinase A
1
2020
51
0.040
 Why?
Drug Evaluation
1
2020
77
0.040
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
55
0.040
 Why?
Medical Oncology
1
2022
229
0.040
 Why?
Time Factors
1
2010
6077
0.040
 Why?
Mutation
1
2010
3338
0.040
 Why?
Nausea
1
2020
99
0.040
 Why?
Lymphatic Metastasis
1
2020
275
0.040
 Why?
Vomiting
1
2020
122
0.040
 Why?
Hospitals
1
2023
581
0.040
 Why?
United States
2
2017
12137
0.040
 Why?
B7-H1 Antigen
1
2020
137
0.040
 Why?
Central Nervous System
1
2020
230
0.040
 Why?
Databases, Factual
1
2023
1125
0.040
 Why?
Genetic Testing
1
2020
381
0.040
 Why?
Xenograft Model Antitumor Assays
1
2020
695
0.040
 Why?
Retreatment
1
2017
67
0.040
 Why?
Academic Medical Centers
1
2020
405
0.040
 Why?
Drug Therapy, Combination
1
2020
949
0.040
 Why?
Clinical Decision-Making
1
2019
268
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
40
0.030
 Why?
Neutrophils
1
2022
1089
0.030
 Why?
Receptor Protein-Tyrosine Kinases
1
2019
224
0.030
 Why?
Erythrocyte Indices
1
2016
27
0.030
 Why?
Anti-Inflammatory Agents
1
2020
445
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2019
239
0.030
 Why?
Drug Resistance, Neoplasm
1
2020
636
0.030
 Why?
Abdominal Neoplasms
1
2015
26
0.030
 Why?
Thoracic Neoplasms
1
2015
31
0.030
 Why?
Tosyl Compounds
1
2015
14
0.030
 Why?
Antibodies, Neoplasm
1
2015
30
0.030
 Why?
Kidney Function Tests
1
2015
140
0.030
 Why?
Neoplasm Grading
1
2015
241
0.030
 Why?
Angiogenesis Inhibitors
1
2016
213
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
117
0.030
 Why?
Radiotherapy
1
2015
175
0.030
 Why?
Organ Size
1
2015
434
0.030
 Why?
Postoperative Period
1
2015
288
0.030
 Why?
Nitriles
1
2015
149
0.030
 Why?
Recurrence
1
2017
925
0.030
 Why?
Demography
1
2015
258
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
124
0.030
 Why?
STAT5 Transcription Factor
1
2014
44
0.030
 Why?
Drug Interactions
1
2015
337
0.030
 Why?
Gonadotropin-Releasing Hormone
1
2015
189
0.030
 Why?
Longitudinal Studies
1
2020
2384
0.030
 Why?
Medication Adherence
1
2017
531
0.030
 Why?
Proportional Hazards Models
1
2015
1078
0.030
 Why?
ErbB Receptors
1
2015
554
0.030
 Why?
Cell Survival
1
2015
1014
0.030
 Why?
Double-Blind Method
1
2016
1656
0.020
 Why?
Biomarkers
1
2022
3397
0.020
 Why?
T-Lymphocytes, Regulatory
1
2014
337
0.020
 Why?
Molecular Targeted Therapy
1
2014
347
0.020
 Why?
Enzyme Inhibitors
1
2014
743
0.020
 Why?
Proto-Oncogene Proteins
1
2014
607
0.020
 Why?
Cell Cycle Proteins
1
2014
549
0.020
 Why?
Logistic Models
1
2015
1829
0.020
 Why?
Animals
2
2020
31565
0.020
 Why?
Mice
1
2020
14843
0.010
 Why?
Adolescent
1
2020
17800
0.010
 Why?
Signal Transduction
1
2014
4501
0.010
 Why?
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (249) concept(s)
_
Co-Authors Expand Description
See all (39) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)